91��

Available Technologies

1 - 1 of 1 Results

A team of ORNL scientists led by Brian Sanders has developed a potent and selective covalent inhibitor of the papain-like protease of SARS-CoV-2. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Development of Covalent Inhibitors of the Papain-like Protease from SARS-CoV-2

There is a critical need for new antiviral drugs for treating infections of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).